11th Nov 2016 13:00
11 November 2016
Result of AGM
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, announces that at the Annual General Meeting, held today, all resolutions were passed.
The slides from the presentation given by the Group will be made available on Clinigen's website www.clinigengroup.com.
- Ends-
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer Martin Abell, Group Chief Financial Officer | |
Matt Parrish, Head of Investor Relations | |
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser)James Black / Tom Ballard (Corporate Broking) | |
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 |
James Steel / Dr Christopher Golden | |
Instinctif Partners (media relations) | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Jayne Crook / Emma Barlow | Email: [email protected] |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L